Immuneering Corporation (IMRX) Income Statement
IMRX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsIMRX revenue and net income
IMRX profit margins
IMRX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
IMRX quarterly EPS vs estimates
Immuneering beat the analyst EPS estimate in 6 of the last 8 quarters. Next report: November 11, 2026 (estimate $-0.29).
IMRX income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $455 | $316,952 | $2.1M | $2.3M | $1.9M |
| Cost of revenue | $698,887 | $713,451 | $764,138 | $158,122 | $1.2M | $1.3M | $1.2M |
| Gross profit | −$698,887 | −$713,451 | −$764,138 | $158,830 | $926,888 | $1.0M | $696,739 |
| Research & development | $42.0M | $48.0M | $41.6M | $36.3M | $26.5M | $15.0M | $4.3M |
| Sales, general & admin | $17.3M | $16.1M | $17.3M | $15.6M | $8.3M | $3.1M | $2.7M |
| Total operating expenses | $58.7M | $64.1M | $58.4M | $51.9M | $34.8M | $18.1M | $7.0M |
| Operating income | −$59.4M | −$64.1M | −$58.4M | −$51.7M | −$33.9M | −$17.1M | −$6.3M |
| Interest income | $3.0M | $2.6M | $3.4M | $1.0M | $169,899 | $42,656 | $57,660 |
| Interest expense | — | — | — | $1.0M | $201,908 | $42,656 | $351,302 |
| Income before taxes | −$56.0M | −$61.0M | −$53.5M | −$50.5M | −$33.8M | −$17.1M | −$7.7M |
| Income taxes | — | — | $2 | −$1.2M | −$307,485 | −$84,336 | $351,302 |
| Net income | −$56.0M | −$61.0M | −$53.5M | −$50.5M | −$33.5M | −$17.0M | −$7.7M |
| EBITDA | −$55.7M | −$63.7M | −$58.1M | −$51.5M | −$33.7M | −$17.0M | −$7.3M |
| EPS (diluted) | −$1.38 | −$2.52 | −$1.89 | −$1.92 | −$3.76 | −$1.26 | −$0.65 |
| Gross margin | — | — | −167,942.4% | 50.1% | 44.6% | 44.6% | 36.3% |
| Operating margin | — | — | −12,837,997.1% | −16,325.8% | −1,629.2% | −739.0% | −327.7% |
| Net margin | — | — | −11,752,004.8% | −15,937.3% | −1,612.3% | −737.2% | −401.6% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $360,958 | $0 | $0 | $0 | $0 | $0 | $726,326 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $180,479 | $180,479 | $612,729 | $86,158 | $91,844 | $175,761 | $174,645 | $175,644 | $175,482 | $187,681 | $185,216 | $195,784 |
| Gross profit | $180,479 | −$180,479 | −$612,729 | −$86,158 | −$91,844 | −$175,761 | −$174,645 | −$175,644 | −$175,482 | −$187,681 | −$185,216 | −$195,784 |
| Research & development | $14.0M | $10.65B | $9.3M | $10.9M | $10.5M | $11.5M | $14.8M | $11.3M | $10.7M | $11.2M | $11.9M | $10.1M |
| Sales, general & admin | $5.0M | $4.68B | $4.5M | $4.5M | $4.3M | $4.0M | $3.7M | $4.0M | $4.3M | $4.2M | $4.4M | $3.9M |
| Total operating expenses | $19.0M | $15.2M | $13.1M | $15.4M | $14.8M | $15.5M | $18.4M | $15.3M | $14.9M | $15.3M | $16.1M | $13.9M |
| Operating income | −$19.0M | −$15.3M | −$13.8M | −$15.4M | −$14.8M | −$15.5M | −$18.6M | −$15.3M | −$14.9M | −$15.3M | −$16.3M | −$13.9M |
| Interest income | $1.1M | $1.4M | $1.9M | $415,831 | $324,013 | $438,520 | $415,240 | $547,072 | $826,104 | $804,884 | $754,144 | $855,532 |
| Interest expense | — | — | — | — | — | — | — | — | — | — | $1.08B | — |
| Income before taxes | −$17.3M | −$13.5M | −$11.6M | −$15.0M | −$14.4M | −$15.0M | −$18.1M | −$14.6M | −$14.1M | −$14.3M | −$15.1M | −$12.6M |
| Income taxes | — | — | — | — | — | — | $328 | $419 | −$473 | −$1 | −$754,656 | −$13.91B |
| Net income | −$17.3M | −$13.5M | −$11.6M | −$15.0M | −$14.4M | −$15.0M | −$18.1M | −$14.6M | −$14.1M | −$14.3M | −$15.1M | −$12.6M |
| EBITDA | −$17.2M | −$15.2M | −$14.1M | −$15.3M | −$14.7M | −$15.4M | −$17.9M | −$15.2M | −$14.8M | −$15.2M | −$14.9M | −$13.8M |
| EPS (diluted) | −$0.27 | −$0.21 | −$0.18 | −$0.38 | −$0.40 | −$0.42 | −$1.07 | −$0.49 | −$0.47 | −$0.49 | −$0.52 | −$0.43 |
| Gross margin | 50.0% | — | — | — | — | — | −24.0% | — | — | — | — | — |
| Operating margin | −5,263.9% | — | — | — | — | — | −2,555.1% | — | — | — | — | — |
| Net margin | −4,784.6% | — | — | — | — | — | −2,485.3% | — | — | — | — | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in IMRX's financial statements (latest annual report filed March 6, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
IMRX financial results
Immuneering reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $56.0 million. Diluted earnings per share came to −$1.38.
See the IMRX stock overview for the latest quote and news, or the IMRX chart for price history and technical indicators.
IMRX income statement FAQ
Does Immuneering have revenue?
Immuneering reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Immuneering profitable?
No. Immuneering reported a net loss of $56.0 million in fiscal 2025.
How much does Immuneering spend on research and development?
Immuneering spent $42.0 million on research and development in fiscal 2025.
What are Immuneering's earnings per share?
Immuneering earned $-1.38 per diluted share in fiscal 2025, compared with $-2.52 a year earlier.
When will Immuneering report its next earnings?
Immuneering is expected to report results for the quarter ending September 30, 2026 on November 11, 2026 before the market opens.
When does Immuneering's fiscal year end?
Immuneering's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 6, 2026.